MX2024002112A - Anticuerpos anti-vegfr1 y sus usos. - Google Patents
Anticuerpos anti-vegfr1 y sus usos.Info
- Publication number
- MX2024002112A MX2024002112A MX2024002112A MX2024002112A MX2024002112A MX 2024002112 A MX2024002112 A MX 2024002112A MX 2024002112 A MX2024002112 A MX 2024002112A MX 2024002112 A MX2024002112 A MX 2024002112A MX 2024002112 A MX2024002112 A MX 2024002112A
- Authority
- MX
- Mexico
- Prior art keywords
- vegfr1
- antibodies
- vegfr1 antibodies
- polynucleotides
- vectors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163233343P | 2021-08-16 | 2021-08-16 | |
| US202263322273P | 2022-03-22 | 2022-03-22 | |
| PCT/US2022/074891 WO2023023465A1 (en) | 2021-08-16 | 2022-08-12 | Anti-vegfr1 antibodies and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002112A true MX2024002112A (es) | 2024-05-03 |
Family
ID=85239767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002112A MX2024002112A (es) | 2021-08-16 | 2022-08-12 | Anticuerpos anti-vegfr1 y sus usos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240425603A1 (https=) |
| EP (1) | EP4388011A4 (https=) |
| JP (1) | JP2024534034A (https=) |
| KR (1) | KR20240046239A (https=) |
| CN (1) | CN119285771A (https=) |
| AU (1) | AU2022331414A1 (https=) |
| CA (1) | CA3229430A1 (https=) |
| CL (1) | CL2024000445A1 (https=) |
| CO (1) | CO2024001686A2 (https=) |
| IL (1) | IL310840A (https=) |
| MX (1) | MX2024002112A (https=) |
| TW (1) | TW202315888A (https=) |
| UY (1) | UY39900A (https=) |
| WO (1) | WO2023023465A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024226943A1 (en) * | 2023-04-26 | 2024-10-31 | Seismic Therapeutic, Inc. | Molecules for modulating the immune system and uses thereof |
| WO2026072909A2 (en) * | 2024-09-27 | 2026-04-02 | Amgen Inc. | Flt1 binding proteins and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3519B1 (ar) * | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
| TW201517916A (zh) * | 2013-03-15 | 2015-05-16 | Lilly Co Eli | Ｖｅｇｆｒ１抗體之治療用途 |
| MX391847B (es) * | 2015-04-07 | 2025-03-21 | Takeda Pharmaceuticals Co | Anticuerpos anti-flt-1 para tratar displasia broncopulmonar. |
| AU2020299600A1 (en) * | 2019-07-03 | 2022-01-06 | Crystal Bioscience Inc. | Anti-CD38 antibody and methods of use thereof |
| CN110452297B (zh) * | 2019-09-03 | 2020-04-14 | 上海洛启生物医药技术有限公司 | 抗vegf单域抗体及其应用 |
-
2022
- 2022-08-12 KR KR1020247008451A patent/KR20240046239A/ko active Pending
- 2022-08-12 CA CA3229430A patent/CA3229430A1/en active Pending
- 2022-08-12 WO PCT/US2022/074891 patent/WO2023023465A1/en not_active Ceased
- 2022-08-12 IL IL310840A patent/IL310840A/en unknown
- 2022-08-12 CN CN202411407118.6A patent/CN119285771A/zh active Pending
- 2022-08-12 MX MX2024002112A patent/MX2024002112A/es unknown
- 2022-08-12 AU AU2022331414A patent/AU2022331414A1/en active Pending
- 2022-08-12 JP JP2024508965A patent/JP2024534034A/ja active Pending
- 2022-08-12 EP EP22859291.1A patent/EP4388011A4/en active Pending
- 2022-08-12 US US18/683,892 patent/US20240425603A1/en active Pending
- 2022-08-15 TW TW111130548A patent/TW202315888A/zh unknown
- 2022-08-15 UY UY0001039900A patent/UY39900A/es unknown
-
2024
- 2024-02-14 CL CL2024000445A patent/CL2024000445A1/es unknown
- 2024-02-16 CO CONC2024/0001686A patent/CO2024001686A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3229430A1 (en) | 2023-02-23 |
| KR20240046239A (ko) | 2024-04-08 |
| EP4388011A4 (en) | 2025-07-30 |
| WO2023023465A1 (en) | 2023-02-23 |
| JP2024534034A (ja) | 2024-09-18 |
| TW202315888A (zh) | 2023-04-16 |
| CN119285771A (zh) | 2025-01-10 |
| UY39900A (es) | 2023-02-28 |
| CL2024000445A1 (es) | 2024-08-23 |
| IL310840A (en) | 2024-04-01 |
| CO2024001686A2 (es) | 2024-02-26 |
| AU2022331414A1 (en) | 2024-04-04 |
| US20240425603A1 (en) | 2024-12-26 |
| EP4388011A1 (en) | 2024-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125429T1 (el) | Μουτεϊνες ιντερλευκινης-21 και μεθοδοι θεραπευτικης αγωγης | |
| EA202192090A1 (ru) | Антигенсвязывающие белки против гамма-цепи рецептора il2 | |
| EA202091859A1 (ru) | Применение антител к sirpa v1 человека и способ получения антител к sirpa v1 | |
| EA202091887A1 (ru) | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры | |
| PH12021550802A1 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof | |
| WO2020076977A3 (en) | Dll3 single domain antibodies and therapeutic compositions thereof | |
| MX2024002112A (es) | Anticuerpos anti-vegfr1 y sus usos. | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| PH12019500600A1 (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| EA202092945A1 (ru) | Различные антигенсвязывающие домены, новые платформы и другие улучшения для клеточной терапии | |
| WO2022081718A8 (en) | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof | |
| EP4706763A3 (en) | Anti-c5 antibodies and uses thereof | |
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| EA201990781A9 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| NO20071788L (no) | Enkelt domene antistoffer mot TNFR1 og fremgangsmater for anvendelse derav. | |
| MX2025012685A (es) | Anticuerpos para claudin6 y metodos para tratar el cancer | |
| EA202090718A1 (ru) | Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1) | |
| MX2024006968A (es) | Anticuerpos cdh17 y metodos de tratamiento del cancer. | |
| AU2018449846A8 (en) | An anti-B7-H3 antibody | |
| NO20082386L (no) | Ligander som har bindingsspesifisitet for EGFR og/eller VEGF og fremgangsmater for anvendelse derav | |
| EA201691482A1 (ru) | Человеческие антитела к pd-1 | |
| EA201792442A1 (ru) | Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение | |
| EP4321171A3 (en) | Sirp alpha-antibody fusion proteins | |
| MA43717B1 (fr) | Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci | |
| MX2021010877A (es) | Moleculas de union a cumulo de diferenciacion 3 (cd3). |